New Antithrombotic Drugs in Acute Coronary Syndrome

In recent years, much progress has been made in the field of antithrombotic drugs in acute coronary syndrome (ACS) treatment, as reflected by the introduction of the more potent P2Y12-inhibitors prasugrel and ticagrelor, and novel forms of concomitant anticoagulation, such as fondaparinux and bivali...

Descripción completa

Detalles Bibliográficos
Autores principales: Zwart, Bastiaan, Parker, William A. E., Storey, Robert F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408919/
https://www.ncbi.nlm.nih.gov/pubmed/32629976
http://dx.doi.org/10.3390/jcm9072059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408919/
https://www.ncbi.nlm.nih.gov/pubmed/32629976
http://dx.doi.org/10.3390/jcm9072059

Ejemplares similares